See more : Banco Bilbao Vizcaya Argentaria, S.A. (BBVA.MC) Income Statement Analysis – Financial Results
Complete financial analysis of BioSig Technologies, Inc. (BSGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioSig Technologies, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Quipt Home Medical Corp. (QIPT) Income Statement Analysis – Financial Results
- The Investment Company plc (INV.L) Income Statement Analysis – Financial Results
- MEMSCAP, S.A. (MEMS.PA) Income Statement Analysis – Financial Results
- OMV Aktiengesellschaft (OMVKY) Income Statement Analysis – Financial Results
- Inventiva S.A. (0RNK.L) Income Statement Analysis – Financial Results
BioSig Technologies, Inc. (BSGM)
About BioSig Technologies, Inc.
BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 18.00K | 286.00K | 441.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 57.00K | 199.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 0.00 | 0.00 | 0.00 | 6.80K |
| Gross Profit | 18.00K | 229.00K | 242.00K | -550.00K | -54.35K | -12.40K | -11.70K | -10.48K | -10.48K | 0.00 | 0.00 | 0.00 | -6.80K |
| Gross Profit Ratio | 100.00% | 80.07% | 54.88% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.09M | 5.82M | 5.60M | 18.14M | 9.74M | 4.37M | 4.76M | 2.65M | 1.24M | 548.00K | 992.21K | 888.95K | 582.53K |
| General & Administrative | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.29M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 72.41K | 0.00 |
| SG&A | 23.08M | 21.38M | 27.85M | 40.95M | 24.81M | 12.88M | 8.14M | 8.50M | 10.80M | 7.30M | 5.23M | 1.36M | 484.13K |
| Other Expenses | 361.00K | 293.00K | 198.00K | 94.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 0.00 | 0.00 |
| Operating Expenses | 28.53M | 27.49M | 33.65M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Cost & Expenses | 28.53M | 27.55M | 33.85M | 59.18M | 34.60M | 17.26M | 12.91M | 11.16M | 12.04M | 7.87M | 6.24M | 2.26M | 1.07M |
| Interest Income | 9.00K | 3.00K | 2.00K | 45.00K | 132.75K | 10.90K | 75.00 | 1.00 | 1.30K | 11.03K | 70.06K | 124.17K | 171.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.90K | 75.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 361.00K | 666.00K | 639.00K | 550.00K | 54.35K | 12.40K | 11.70K | 10.48K | 10.48K | 15.81K | 17.06K | 10.02K | 6.80K |
| EBITDA | -28.15M | -26.97M | -33.21M | -58.63M | -34.42M | -17.25M | -13.11M | -10.73M | -9.45M | -7.85M | -6.22M | -2.25M | -1.14M |
| EBITDA Ratio | -156,394.44% | -9,430.77% | -7,656.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -28.51M | -27.27M | -33.41M | -59.18M | -34.60M | -17.26M | -12.91M | -11.16M | -12.04M | -7.87M | -6.24M | -2.26M | -1.07M |
| Operating Income Ratio | -158,400.00% | -9,533.22% | -7,576.19% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -178.00K | 3.00K | 555.00K | 44.00K | 133.20K | 10.90K | 210.54K | -422.91K | 2.58M | -604.80K | -3.57M | -124.17K | -77.76K |
| Income Before Tax | -28.69M | -27.26M | -32.86M | -59.14M | -34.47M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.39M | -1.15M |
| Income Before Tax Ratio | -159,388.89% | -9,532.17% | -7,450.34% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 9.00K | -1.49M | -6.97M | -549.05K | 21.79K | -210.54K | 422.91K | -2.58M | 11.03K | 70.06K | 90.86K | 0.00 |
| Net Income | -29.04M | -27.27M | -31.36M | -52.17M | -33.92M | -17.25M | -12.70M | -11.59M | -9.46M | -8.47M | -9.80M | -2.48M | -1.15M |
| Net Income Ratio | -161,338.89% | -9,535.31% | -7,111.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| EPS Diluted | -3.95 | -6.33 | -9.36 | -18.70 | -16.39 | -11.89 | -12.42 | -14.86 | -16.77 | -21.95 | -29.94 | -0.76 | -4.43 |
| Weighted Avg Shares Out | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
| Weighted Avg Shares Out (Dil) | 7.35M | 4.31M | 3.35M | 2.79M | 2.07M | 1.45M | 1.02M | 779.63K | 564.12K | 386.01K | 327.51K | 3.26M | 266.00K |
BioSig Technologies enters deal for Cleveland Clinic to evaluate its PURE EP signal processing platform
BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into an evaluation agreement for its PURE EP System with Cleveland Clinic, its first following the induction of a new commercialization team to accelerate the process from product evaluation to adoption. The medical...
BioSig: PURE EP Economics Trade Exhausted
Despite numerous positive updates around its PURE EP segment, the market is agnostic in directional movements on the chart. Whilst the muddy waters on its PURE EP economics have been somewhat cleared, many uncertainties remain.
BioSig targets July 1 to launch national PURE EP commercial campaign
BioSig Technologies Inc plans to kick off a national commercial launch campaign for its PURE EP System on July 1, 2022 following multiple initiatives to accelerate its transition from limited market release to nationwide availability. BioSig has more than 30 qualified leads ahead of the...
BioSig Advances its PURE™ System Commercial Launch to Medical Centers Nationwide
Westport, CT, May 26, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced the rollout...
BioSig's PURE EP™ System to be Featured During EPLive 2022
The Company's flagship technology to be featured during a two-day educational conference that draws the world's top cardiac electrophysiology experts The Company's flagship technology to be featured during a two-day educational conference that draws the world's top cardiac electrophysiology experts
BioSig maintains ‘Outperform' rating from Noble Capital as "stronger commercialization efforts” underway for its PURE EP system
BioSig Technologies Inc drew an ‘Outperform' rating from Noble Capital, which noted that "stronger commercialization efforts” are underway for the company's PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems after the first quarter. In a note to clients, Noble Capital analysts...
BioSig Technologies CEO Kenneth Londoner says the company has made great strides as it accelerates commercial momentum for its PURE EP system
BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Kenneth Londoner said the company has made great strides on multiple fronts as it accelerates commercial momentum for developing a national installed base of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP systems. In...
BioSig Technologies, Inc. Issues Shareholder Letter with Corporate Update on Recent Achievements
Westport, CT, May 11, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the "Company"), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today issued a Letter...
BioSig to Present at Heart Rhythm 2022
Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software Company's conference program to include physician presentations and technology demonstrations, including features of its newly released PURE EP(TM) Nova-5 Software
BioSig to Present at NobleCon18 Capital Markets Conference
Westport, CT, April 07, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and...
Source: https://incomestatements.info
Category: Stock Reports